Revance News

RVNCDelisted Stock  USD 3.65  0.00  0.00%   
About 53% of Revance's investor base is interested to short. The analysis of current outlook of investing in Revance suggests that many traders are impartial regarding Revance's prospects. The current market sentiment, together with Revance's historical and current headlines, can help investors time the market. In addition, many technical investors use Revance stock news signals to limit their universe of possible portfolio assets.
  
over a month ago at gurufocus.com         
Disposition of 120000 shares by Hollander David of Revance subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a month ago at www.macroaxis.com         
Disposition of 120000 shares by Hollander David of Revance subject to Rule 16b-3
Macroaxis News
over a month ago at www.macroaxis.com         
Disposition of 120000 shares by Hollander David of Revance subject to Rule 16b-3
Macroaxis News
over a month ago at globenewswire.com         
Disposition of 120000 shares by Hollander David of Revance subject to Rule 16b-3
Macroaxis News: globenewswire.com
over a month ago at globenewswire.com         
Class Action Filed Against Revance Therapeutics, Inc. Seeking Recovery for Investors Contact Levi Ko...
Macroaxis News: globenewswire.com
over a month ago at gurufocus.com         
GLAZER CAPITAL, LLC Acquires Significant Stake in Revance Therapeutics Inc
Gurufocus Stories at Macroaxis
over a month ago at gurufocus.com         
Disposition of 15000 shares by Russell Angus C. of Revance subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a month ago at gurufocus.com         
RVNC INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Revance Therapeutics, ...
Gurufocus Stories at Macroaxis
over a month ago at prnewswire.com         
Revance Therapeutics, Inc. Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsui...
prnewswire News
over a month ago at globenewswire.com         
RVNC INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Revance Therapeutics, Inc. Invest...
Macroaxis News: globenewswire.com
over a month ago at globenewswire.com         
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeuti...
Macroaxis News: globenewswire.com
over a month ago at gurufocus.com         
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance ...
Gurufocus Stories at Macroaxis
over a month ago at bizjournals.com         
Revance Therapeutics sells to Crown Laboratories
bizjournals News
over a month ago at finance.yahoo.com         
Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
Yahoo News
over a month ago at globenewswire.com         
Levi Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. of a Class Action Lawsuit and an ...
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about Revance that are available to investors today. That information is available publicly through Revance media outlets and privately through word of mouth or via Revance internal channels. However, regardless of the origin, that massive amount of Revance data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Revance news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Revance relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Revance's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Revance alpha.

Revance Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Deadline Alert Revance Therapeutics, Inc. ...
01/27/2025
2
Revance Therapeutics, Inc. Class Action Lawsuit Alert Johnson Fistel Announces Shareholders with Losses Should Contact the Law Firm for More Information
01/31/2025
3
DEADLINE ALERT for NXT, RVNC, REGN, BIOA Law Offices of Howard G. ...
02/03/2025
4
Levi Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. of a Class Action Lawsuit and an Upcoming Deadline
02/04/2025
5
Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
02/05/2025
6
Revance Therapeutics, Inc. Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
02/06/2025
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Consideration for investing in Revance Stock

If you are still planning to invest in Revance check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance's history and understand the potential risks before investing.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments